Home › Articles › Shingles vaccine: cardiovascular protection suggested by observational studies
Specialties

Shingles vaccine: cardiovascular protection suggested by observational studies

1 May 20267 min readClinovus AI Team

Shingles is not just a painful skin disease. Data from 2025–2026, confirmed at ACC 2026, show that VZV reactivation triggers an inflammatory cascade with measurable cardiovascular consequences. The vaccine offers protection well beyond shingles prevention alone.

Key figures: cohort study of 1.27 million people

The pivot study is Korean: over 1.27 million people aged 50+, followed for 6 years, published in the European Heart Journal.[1]

Cardiovascular risk reduction by the shingles vaccine Overall cardiovascular risk −23%Major events (stroke, MI, death) −26%Heart failure −26%Cerebrovascular events −24%Coronary artery disease −22% Kyung Hee University, Seoul · European Heart Journal · 1.27 million participants · 6-year follow-up
Cardiovascular risk reduction after shingles vaccination — cohort study of 1.27 million people

Protection is observed for 8 years, with peak efficacy at 2–3 years. The effect is strongest in men, those under 60 and people with unhealthy lifestyles.

The mechanism: why shingles damages the heart

How shingles increases cardiovascular risk — and how the vaccine protects VZV reactivation Latent varicella-zoster virus Systemic inflammation Pro-inflammatory cytokines Hypercoagulability Arterial & venous thrombosis Endothelial damage Vasculitis, vascular dysfunction ↑ Risk stroke, MI, HF Within 12 months of shingles Shingles vaccine → prevents reactivation → blocks the cascade 2026 observational study: possible lower dementia risk · Shingrix® · >65 yrs
Shingles increases cardiovascular risk via inflammation and coagulation — the vaccine blocks this cascade upstream

ACC 2026: new data on Shingrix®

ACC 2026 data confirm the protective effect of Shingrix® in patients with existing cardiovascular disease — significant reduction in heart attacks, strokes, heart failure and death in the year following vaccination.[2]

The protective effect is likely due to prevention of the systemic inflammation and dangerous blood clots resulting from shingles. By preventing viral reactivation, the vaccine cuts the cascade upstream.

A possible benefit: lower dementia risk

An observational study published in Nature (February 2026, to be verified) of 65,800 Shingrix®-vaccinated people and 263,200 controls associates two doses with a dementia risk about twice as low in people over 65.[3]

Recommendations for practice in Italy

See also our article on SOAP notes with AI from your dictation.

Frequently asked questions

Is the shingles vaccine recommended in Italy?

Yes. Under Italy's National Vaccine Prevention Plan (PNPV), the recombinant vaccine (Shingrix®, 2 doses) is offered at age 65 and to at-risk individuals from age 18; check the regional schedule. Zostavax® is no longer available.

How does shingles increase cardiovascular risk?

VZV reactivation triggers systemic inflammation, hypercoagulability and endothelial damage — explaining the documented increased risk of stroke, MI and heart failure within 12 months of a shingles episode.

Do the cardiovascular benefits apply to Shingrix® too?

The Korean mega-study concerned Zostavax®. ACC 2026 data confirm the protective effect of Shingrix® in cardiac patients. The Nature study (February 2026) on dementia specifically concerned Shingrix®.

Should patients vaccinated with Zostavax® be re-vaccinated?

Yes. Zostavax® is no longer available and its protection wanes. Shingrix® can be given after at least 2 months. Its immunogenicity and efficacy exceed Zostavax®, with protection maintained beyond 10 years.

Sources and references

  1. Yon DK et al. (2025). Zoster vaccination and cardiovascular events — cohort of 1.27 million. European Heart Journal. medscape.com
  2. ACC 2026. Shingrix® and reduction of major cardiovascular events in high-risk patients. vih.org
  3. Nature (February 2026). Shingrix® and dementia risk in over-65s (observational study).
  4. Italian Ministry of Health. National Vaccine Prevention Plan (PNPV) 2023-2025 — herpes zoster. salute.gov.it
  5. Ma-Clinique.fr (March 2026). Shingles vaccine and cardiovascular risk reduction. ma-clinique.fr
Disclaimer: this article does not replace official vaccination recommendations (Italy's PNPV and regional schedules). Vaccination decisions must be individualised.

Document your vaccination consultations with Clinovus AI

Vaccination history, SOAP note — structured from your dictation, for you to review and sign. Hosted in Switzerland.

Try free →
A question about this article?Our team replies within 24h.
support@clinovusai.com